|
18 Mar 2025 |
Carysil
|
Consensus Share Price Target
|
685.55 |
996.50 |
- |
45.36 |
buy
|
|
|
|
|
09 Nov 2024
|
Carysil
|
Edelweiss
|
685.55
|
936.00
|
812.90
(-15.67%)
|
36.53 |
Buy
|
|
|
Healthy Volume but higher cost squeeze profits
|
|
05 Aug 2024
|
Carysil
|
CD Equisearch
|
685.55
|
909.00
|
764.25
(-10.30%)
|
Target met |
Accumulate
|
|
|
|
|
22 May 2024
|
Carysil
|
Edelweiss
|
685.55
|
987.00
|
856.60
(-19.97%)
|
43.97 |
Buy
|
|
|
Integration costs along with slow domestic growth hurt performance
|
|
02 Feb 2024
|
Carysil
|
Edelweiss
|
685.55
|
1044.00
|
926.65
(-26.02%)
|
Target met |
Buy
|
|
|
Growth momentum continues; outlook robust
|
|
09 Nov 2023
|
Carysil
|
Edelweiss
|
685.55
|
905.00
|
761.80
(-10.01%)
|
Target met |
Buy
|
|
|
Growth momentum back on track; outlook robust
|
|
17 Aug 2023
|
Carysil
|
StoxBox - BP Wealth
|
685.55
|
|
636.00
(7.79%)
|
|
Results Update
|
|
|
In Q1FY24, Carysil Ltd. reported a revenue decline of 2.7% QoQ / 17.3% YoY to Rs. 171.3 crores in Q1FY24 owing to lower production and sales due to SAP implementation in April 2023, thus missing market expectations of Rs. 160.2 crores. On a sequential basis, the GP and EBITDA margins improved 176 bps / 38 bps to 49.9% and 18.4%, respectively, with the normalization in freight and other input costs of the business which outweighed an uptick in employee expenses.
|
|
14 Aug 2023
|
Carysil
|
Edelweiss
|
685.55
|
790.00
|
643.25
(6.58%)
|
Target met |
Buy
|
|
|
Growth to accelerate from Q2; outlook robust
|
|
07 Aug 2023
|
Carysil
|
CD Equisearch
|
685.55
|
776.00
|
699.65
(-2.02%)
|
Target met |
Accumulate
|
|
|
|
|
29 May 2023
|
Carysil
|
Edelweiss
|
685.55
|
786.00
|
557.65
(22.94%)
|
Target met |
Buy
|
|
|
Inline numbers: order inflows improve
|
|
06 Apr 2023
|
Carysil
|
Monarch Networth Capital Limited
|
685.55
|
780.00
|
600.60
(14.14%)
|
Target met |
Buy
|
|
|
|
|
28 Feb 2023
|
Carysil
|
KamayaKya Wealth
|
685.55
|
639.00
|
512.40
(33.79%)
|
Target met |
Buy
|
|
|
Going forward, we estimate 25%, 24% and 19% Revenue, EBITDA and PAT CAGR respectively till FY24, driven by improvement in demand from exports and an increase in the utilization of the existing capacities. Further the increased focus on domestic business will help the company to scale its brand Carysil.
|
|
30 Jul 2022
|
Carysil
|
CD Equisearch
|
685.55
|
741.00
|
653.25
(4.94%)
|
Target met |
Accumulate
|
|
|
|
|
30 Nov 2021
|
Carysil
|
CD Equisearch
|
685.55
|
994.00
|
810.35
(-15.40%)
|
|
Buy
|
|
|
Despite the pandemic-induced lockdowns the global home improvement industry has seen little moderation in demand over the past year, all thanks to rising mortgage & interest rates and surging new home prices that are driving spending in home improvement activities. This growing trend of renovation has in turn has shifted consumer interest toward modern...
|